40.55 USD
↘ 0.22 (0.54%)LIVE (AS OF 12:11 PM EDT)
Supernus Pharmaceuticals, Inc.
SUPNNASDAQ • USD
Market: OPEN
Supernus Pharmaceuticals, Inc. (SUPN) is currently trading at $40.55. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place SUPN at a fair price relative to peers.
Technical & fundamental data as of Oct 26, 2026.
Open?$40.57
High?$41.04
Low?$39.59
Prev. Close?$40.77
Volume?353.3K
Avg. Volume?852.3K
VWAP?$40.33
Rel. Volume?0.41x
Bid / Ask
Bid?$34.81 × 100
Ask?$40.60 × 200
Spread?$5.79
Midpoint?$37.71
Valuation & Ratios
Market Cap?2.4B
Shares Out?58.2M
Float?55.5M
Float %?95.4%
P/E Ratio?N/A
P/B Ratio?2.30
EPS?-$1.89
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Employees
778
Market Cap
2.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2012-05-01
Address
9715 KEY WEST AVENUE
ROCKVILLE, MD 20850
Phone: 301-838-2500
ROCKVILLE, MD 20850
Phone: 301-838-2500
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?97
Momentum?33
Short Sent.?70
Piotroski F-Score?1/9Weak
Altman Z-Score?4.63Safe
Confidence?55%Low
Short InterestElevated
Short % of Float?7.28%Elevated
Short Interest?4.0M
Days to Cover?4.9
Free Float55.5M
Avg Daily Volume819.9K
Settlement Date2026-10-15
Financial Health
Current Ratio?2.08Strong
Quick Ratio?1.84Adequate
Cash Ratio?0.52Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score73/100
P/E?N/A▾
P/B?2.30CHEAP▾
Peers100
S&P68
P/S?2.86CHEAP▾
Peers100
S&P52
P/FCF?126.4PRICEY▾
Peers100
S&P3
EV/EBITDA?76.9HIGH▾
Peers100
S&P3
EV/Sales?2.64CHEAP▾
Peers100
S&P66
Returns & Efficiency
ROE?-10.7%WEAK▾
S&P9
ROA?-7.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$18.8M
Enterprise Value?$2.2B
Fundamentals ratios updated end of day